BR0314372A - Compostos imidazol como inibidores do fator de crescimento tranformador (tgf) - Google Patents
Compostos imidazol como inibidores do fator de crescimento tranformador (tgf)Info
- Publication number
- BR0314372A BR0314372A BR0314372-4A BR0314372A BR0314372A BR 0314372 A BR0314372 A BR 0314372A BR 0314372 A BR0314372 A BR 0314372A BR 0314372 A BR0314372 A BR 0314372A
- Authority
- BR
- Brazil
- Prior art keywords
- tgf
- growth factor
- transforming growth
- inhibitors
- imidazole compounds
- Prior art date
Links
- 102000009618 Transforming Growth Factors Human genes 0.000 title abstract 6
- 108010009583 Transforming Growth Factors Proteins 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000002460 imidazoles Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical class C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 derivatives thereof Chemical class 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS IMIDAZOL COMO INIBIDORES DO FATOR DE CRESCIMENTO TRANSFORMADOR (TGF)". A presente invenção refere-se a compostos imidazol, incluindo derivados destes, intermediários para a sua preparação, composições farmacêuticas que os contêm e o seu uso medicinal. Os compostos da presente invenção são inibidores potentes da via de sinalização do fator de crescimento transformador ('TGF')-<225>. Eles são úteis no tratamento de estados de doença relacionados com TGF-<225> incluindo, por exemplo, câncer e doenças fibróticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41189402P | 2002-09-18 | 2002-09-18 | |
| US48452203P | 2003-07-02 | 2003-07-02 | |
| PCT/IB2003/003833 WO2004026859A1 (en) | 2002-09-18 | 2003-09-08 | Novel imidazole compounds as transforming growth factor (tgf) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314372A true BR0314372A (pt) | 2005-07-19 |
Family
ID=32033577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314372-4A BR0314372A (pt) | 2002-09-18 | 2003-09-08 | Compostos imidazol como inibidores do fator de crescimento tranformador (tgf) |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7153872B2 (pt) |
| EP (1) | EP1542990B1 (pt) |
| JP (1) | JP4547271B2 (pt) |
| KR (1) | KR20050057392A (pt) |
| CN (1) | CN1681805A (pt) |
| AP (1) | AP2005003264A0 (pt) |
| AR (1) | AR041274A1 (pt) |
| AT (1) | ATE433968T1 (pt) |
| AU (1) | AU2003263404A1 (pt) |
| BR (1) | BR0314372A (pt) |
| CA (1) | CA2498047C (pt) |
| CO (1) | CO5550453A2 (pt) |
| DE (1) | DE60328028D1 (pt) |
| EA (1) | EA200500378A1 (pt) |
| EC (1) | ECSP055680A (pt) |
| ES (1) | ES2325687T3 (pt) |
| HR (1) | HRP20050252A2 (pt) |
| IS (1) | IS7712A (pt) |
| MA (1) | MA27441A1 (pt) |
| MX (1) | MXPA05002981A (pt) |
| NO (1) | NO20051008L (pt) |
| OA (1) | OA12928A (pt) |
| PA (1) | PA8583301A1 (pt) |
| PE (1) | PE20050072A1 (pt) |
| PL (1) | PL375980A1 (pt) |
| TW (1) | TW200404793A (pt) |
| UY (1) | UY27982A1 (pt) |
| WO (1) | WO2004026859A1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| CN1681805A (zh) * | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| WO2004026306A2 (en) * | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| KR100749566B1 (ko) | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| MXPA06014909A (es) | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| JP2008511631A (ja) * | 2004-08-31 | 2008-04-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール |
| US20070275968A1 (en) * | 2004-09-07 | 2007-11-29 | Hitoshi Kurata | Substituted Biphenyl Derivative |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| CN101330914A (zh) * | 2005-12-16 | 2008-12-24 | 爱尔康公司 | 使用alk5调节剂控制眼内压 |
| CN1990473B (zh) * | 2005-12-30 | 2013-07-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 三取代1h-咪唑类化合物、其制备方法、药物组合物及其制药用途 |
| WO2008094556A2 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| EP2154965A4 (en) * | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| WO2009115572A2 (en) * | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8324241B2 (en) | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| WO2009126861A2 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
| EP2300466B1 (en) | 2008-06-20 | 2014-08-06 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| PE20121048A1 (es) | 2009-06-26 | 2012-08-25 | Novartis Ag | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 |
| DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| PL3089971T3 (pl) | 2014-01-01 | 2021-01-25 | Medivation Technologies Llc | Związki i sposoby ich zastosowania |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| US10961239B2 (en) | 2017-01-05 | 2021-03-30 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CA3117710A1 (en) | 2018-12-11 | 2020-06-18 | Theravance Biopharma R&D Ip, Llc | Alk5 inhibitors |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| KR20220104208A (ko) * | 2019-11-22 | 2022-07-26 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린 |
| KR102539660B1 (ko) | 2020-08-20 | 2023-06-02 | 가천대학교 산학협력단 | 베타-폴리비닐리덴 플루오라이드 코팅층이 형성된 아연 음극 및 상기 음극을 포함하는 수계 아연 이온 전지 |
| KR102733584B1 (ko) | 2020-09-04 | 2024-11-21 | 고려대학교 세종산학협력단 | 전기화학적 및 광전기화학적 수소 생산용 황화니켈 나노결정 촉매 및 이의 제조방법 |
| US12240830B2 (en) * | 2021-08-13 | 2025-03-04 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds and use thereof |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
| CN119241538A (zh) * | 2024-09-30 | 2025-01-03 | 陕西科技大学 | 一类三唑并吡啶结构的化合物、合成方法及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) * | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| IL83467A0 (en) * | 1986-08-15 | 1988-01-31 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US5932576A (en) | 1997-05-22 | 1999-08-03 | G. D. Searle & Company | 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| AU4798000A (en) * | 1999-04-09 | 2000-11-14 | Smithkline Beecham Corporation | Triarylimidazoles |
| AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| EP1349851A4 (en) | 2000-11-16 | 2004-09-08 | Smithkline Beecham Corp | COMPOUNDS |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| WO2002062787A1 (en) | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| ATE291020T1 (de) | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| WO2002072576A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| EP1539748A1 (en) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| KR20050057441A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인코포레이티드 | 전환 성장 인자 억제제로서의 신규한 아이소티아졸 및아이속사졸 화합물 |
| CN1681805A (zh) * | 2002-09-18 | 2005-10-12 | 辉瑞产品公司 | 作为转化生长因子(tgf)抑制剂的新的咪唑类化合物 |
| JP2006502236A (ja) | 2002-09-18 | 2006-01-19 | ファイザー・プロダクツ・インク | 形質転換成長因子（ｔｇｆ）阻害剤としてのトリアゾール誘導体 |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
-
2003
- 2003-09-08 CN CNA038221608A patent/CN1681805A/zh active Pending
- 2003-09-08 WO PCT/IB2003/003833 patent/WO2004026859A1/en not_active Ceased
- 2003-09-08 AP AP2005003264A patent/AP2005003264A0/xx unknown
- 2003-09-08 EA EA200500378A patent/EA200500378A1/ru unknown
- 2003-09-08 CA CA002498047A patent/CA2498047C/en not_active Expired - Fee Related
- 2003-09-08 JP JP2004568901A patent/JP4547271B2/ja not_active Expired - Fee Related
- 2003-09-08 DE DE60328028T patent/DE60328028D1/de not_active Expired - Lifetime
- 2003-09-08 ES ES03797429T patent/ES2325687T3/es not_active Expired - Lifetime
- 2003-09-08 OA OA1200500077A patent/OA12928A/en unknown
- 2003-09-08 HR HR20050252A patent/HRP20050252A2/hr not_active Application Discontinuation
- 2003-09-08 EP EP03797429A patent/EP1542990B1/en not_active Expired - Lifetime
- 2003-09-08 AU AU2003263404A patent/AU2003263404A1/en not_active Abandoned
- 2003-09-08 AT AT03797429T patent/ATE433968T1/de not_active IP Right Cessation
- 2003-09-08 BR BR0314372-4A patent/BR0314372A/pt not_active IP Right Cessation
- 2003-09-08 KR KR1020057004570A patent/KR20050057392A/ko not_active Ceased
- 2003-09-08 MX MXPA05002981A patent/MXPA05002981A/es active IP Right Grant
- 2003-09-08 PL PL03375980A patent/PL375980A1/xx not_active Application Discontinuation
- 2003-09-16 UY UY27982A patent/UY27982A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103358A patent/AR041274A1/es unknown
- 2003-09-16 PE PE2003000942A patent/PE20050072A1/es not_active Application Discontinuation
- 2003-09-17 TW TW092125609A patent/TW200404793A/zh unknown
- 2003-09-17 PA PA20038583301A patent/PA8583301A1/es unknown
- 2003-09-17 US US10/666,192 patent/US7153872B2/en not_active Expired - Fee Related
-
2005
- 2005-02-24 IS IS7712A patent/IS7712A/is unknown
- 2005-02-24 NO NO20051008A patent/NO20051008L/no unknown
- 2005-03-17 EC EC2005005680A patent/ECSP055680A/es unknown
- 2005-03-17 CO CO05024820A patent/CO5550453A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28155A patent/MA27441A1/fr unknown
-
2006
- 2006-11-10 US US11/558,624 patent/US7635702B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05002981A (es) | 2005-06-22 |
| NO20051008L (no) | 2005-06-07 |
| ATE433968T1 (de) | 2009-07-15 |
| JP2006502237A (ja) | 2006-01-19 |
| AR041274A1 (es) | 2005-05-11 |
| CA2498047C (en) | 2009-05-19 |
| CN1681805A (zh) | 2005-10-12 |
| PE20050072A1 (es) | 2005-03-01 |
| TW200404793A (en) | 2004-04-01 |
| EA200500378A1 (ru) | 2005-08-25 |
| KR20050057392A (ko) | 2005-06-16 |
| CA2498047A1 (en) | 2004-04-01 |
| US20070088037A1 (en) | 2007-04-19 |
| AP2005003264A0 (en) | 2005-03-31 |
| WO2004026859A1 (en) | 2004-04-01 |
| US7635702B2 (en) | 2009-12-22 |
| US20040106608A1 (en) | 2004-06-03 |
| OA12928A (en) | 2006-10-13 |
| DE60328028D1 (de) | 2009-07-30 |
| ECSP055680A (es) | 2005-05-30 |
| PA8583301A1 (es) | 2004-09-16 |
| MA27441A1 (fr) | 2005-07-01 |
| US7153872B2 (en) | 2006-12-26 |
| UY27982A1 (es) | 2004-04-30 |
| EP1542990A1 (en) | 2005-06-22 |
| AU2003263404A1 (en) | 2004-04-08 |
| IS7712A (is) | 2005-02-24 |
| EP1542990B1 (en) | 2009-06-17 |
| JP4547271B2 (ja) | 2010-09-22 |
| ES2325687T3 (es) | 2009-09-14 |
| PL375980A1 (en) | 2005-12-12 |
| CO5550453A2 (es) | 2005-08-31 |
| HRP20050252A2 (en) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0314577A (pt) | Derivados de triazol como inibidores do fator de crescimento de transformação (tgf) | |
| BR0314383A (pt) | Compostos de oxazol e tiazol como inibidores do fator de crescimento transformante(tgf) | |
| BR0314302A (pt) | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) | |
| BRPI0408251A (pt) | compostos de pirazina como inibidores do fator de crescimento transformante (tgf) | |
| BR0314286A (pt) | Compostos de isotiazol e isoxazol como inibidores do fator de crescimento transformante (tgf) | |
| BRPI0407999A (pt) | compostos heteroaromáticos fundidos como inibidores do fator de transformação do crescimento (tgf) | |
| ECSP055680A (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| RU2325389C2 (ru) | Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0209774A (pt) | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento | |
| BRPI0415525A (pt) | derivados de imidazola e seu uso como agentes farmacêuticos | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| BR0215312A (pt) | Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| CY1111256T1 (el) | Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους | |
| BR0012610A (pt) | Novo derivado de difenilpiperidina | |
| ATE312815T1 (de) | Neue verbindungen | |
| DE60215313D1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| MXPA06003374A (es) | Derivados de bencimidazolona y quinazolinona como agonistas en receptores semejantes al receptor opioide 1 de humano. | |
| BR0014233A (pt) | Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação | |
| BR0309412A (pt) | Indol-2-onas como inibidores seletivos da ciclooxigenase-2 | |
| UA83870C2 (ru) | Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1 | |
| TW200634002A (en) | Chemical compounds | |
| DOP2003000712A (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012. |